4 completed, 1 withdrawn. 2 Phase 2, 1 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Withdrawn 1 |
Follow relebactam: new trials by email Literature Review of relebactam trials Research Report on relebactam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients Imipenem/Cilastatin/Relebactam 1.25g - Obesity, Critical Illness | Phase 4 | Withdrawn | University of Illinois at Chicago | 2023-01-01 | 2024-11-27 | |
| Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) Imipenem, Relebactam, Cilastatin - Bacterial Pneumonia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 537 | 2015-11-24 | 2020-04-16 |
| Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004) Relebactam 250 mg, Relebactam 125 mg, Imipenem/cilastatin - Intra-abdominal Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 351 | 2012-06-01 | 2019-06-10 |
| Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003) Relebactam 250 mg, Relebactam 125 mg, imipenem/cilastatin 500 mg - Urinary Tract Infections, Pyelonephritis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 302 | 2012-05-16 | 2019-05-24 |
| A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005) MK-7655, Imipenem + Cilastatin, Caffeine - Infectious Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 49 | 2011-01-28 | 2020-06-11 |
Communicable Diseases (1) · Critical Illness (1) · Intraabdominal Infections (1) · Obesity (1) · Pneumonia, Bacterial (1) · Pyelonephritis (1) · Urinary Tract Infections (1) · Urologic Diseases (1)
Merck Sharp & Dohme LLC (4) · University of Illinois at Chicago (1)
United States (1)
PMID 27503659, PMID 28575389, PMID 31856304, PMID 32785589, PMID 34704389, PMID 37383243, PMID 41586496, PMID 42743113
2015 (1)